NCT01612351 2026-03-17
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
Clinical Trials
47 trialsNCT02158507 2026-01-22
Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
University of Alabama at Birmingham
Phase NA Completed
NCT01382706 2025-10-09
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder
University of Southern California
Phase 2 Terminated
NCT04608409 2025-06-29
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
University of Kentucky
Phase 1 Completed
NCT01273610 2025-06-10
Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00999804 2025-03-12
HELEX
Baylor Breast Care Center
Phase 2 Active not recruiting
NCT00881621 2025-03-03
Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer
Georgetown University
Phase 2 Terminated
NCT00470704 2024-12-19
Lapatinib in Combination With Trastuzumab in Patients With HER2-Positive, Metastatic Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01873833 2023-10-05
Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer
University of Southern California
Phase 2 Terminated
NCT00841828 2023-03-31
Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients
Spanish Breast Cancer Research Group
Phase 2 Completed
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT01499160 2022-02-11
Letrozole and Lapatinib Followed by Everolimus in Women With Advanced Breast Cancer
University of Maryland, Baltimore
Phase 2 Terminated
NCT00952692 2021-12-20
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer
Duke University
Phase 1/2 Completed
NCT00206427 2021-09-29
GW
Baylor Breast Care Center
Phase 2 Completed
NCT02073487 2021-09-22
TEAL
The Methodist Hospital Research Institute
Phase 2 Completed
NCT00863122 2021-01-12
Concentration and Activity of Lapatinib in Vestibular Schwannomas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT00883688 2020-08-26
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01044433 2020-03-19
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT00331630 2020-03-06
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
Northwestern University
Phase EARLY_PHASE1 Completed
NCT00939523 2020-01-22
Targeted Therapy With Lapatinib in Patients With Recurrent Pituitary Tumors Resistant to Standard Therapy
Cedars-Sinai Medical Center
Phase 2 Completed
NCT00574171 2019-12-18
Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma
University of Wisconsin, Madison
Phase 2 Completed
NCT01827163 2019-12-18
Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01118975 2019-11-13
GCC 0845:Vorinostat and Lapatinib in Advanced Solid Tumors and Advanced Breast Cancer to Evaluate Response and Biomarkers
University of Maryland, Baltimore
Phase 1/2 Terminated
NCT00548184 2019-11-07
Lapatinib and Trastuzumab With or Without Endocrine Therapy
Baylor Breast Care Center
Phase 2 Completed
NCT00820872 2019-10-21
Docetaxel, Carboplatin, Trastuzumab, and Lapatinib in Treating Patients With Early Stage Breast Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT01891357 2019-09-17
Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer
West German Study Group
Phase 2 Terminated
NCT00759642 2019-07-01
Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy
University of Kansas Medical Center
Phase 2 Terminated
NCT00953576 2018-09-04
KHLAD
Dana-Farber Cancer Institute
Phase 1/2 Terminated
NCT00225758 2018-07-27
Lapatinib in Metastatic Breast Cancer Resistant to Hormone Therapy
Dartmouth-Hitchcock Medical Center
Phase 2 Terminated
NCT00404066 2017-12-22
Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer
Stanford University
Phase 2 Completed
NCT00721630 2017-08-15
Novel Capecitabine Dosing Schedule in Combination With Lapatinib, Based on the Norton-Simon Mathematical Method in Patients With HER2 Overexpressed/Amplified, Trastuzumab (Herceptin) -Refractory, Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01934894 2017-07-02
Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00246753 2017-06-28
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT01868503 2017-06-26
Lapatinib Ditosylate and Radiation Therapy in Treating Patients With Locally Advanced or Locally Recurrent Breast Cancer
Stanford University
Phase 2 Terminated
NCT00482391 2017-05-12
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00496366 2017-03-21
Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00490061 2017-03-06
Lapatinib and Radiation for Stage III-IV Head and Neck Cancer Patients Who Cannot Tolerate Concurrent Chemotherapy
Stanford University
Phase 2 Terminated
NCT01769508 2016-06-13
Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer
SCRI Development Innovations, LLC
Phase 2 Terminated
NCT00973739 2016-03-22
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
NYU Langone Health
Phase 2 Completed
NCT00857714 2015-07-08
Lapatinib for Treatment of Ductal Carcinoma In Situ (DCIS) of the Breast
Indiana University
Phase NA Terminated
NCT00632489 2015-06-08
LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients
SCRI Development Innovations, LLC
Phase 1 Completed
NCT00756470 2014-11-17
Phase II Neoadjuvant in Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01272141 2014-09-22
A Study of Lapatinib in Combination With Everolimus in Patients With Advanced, Triple Negative Breast Cancer
Emory University
Phase 2 Terminated
NCT00470847 2014-05-22
Lapatinib in Combination With Radiation Therapy in Patients With Brain Metastases From HER2-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00436644 2014-04-16
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Mayo Clinic
Phase 2 Completed
NCT00499681 2012-08-10
PhII Neo-Adjuvant Letrozole & Lapatinib in Pts w/HER2+ & Hormone Receptor+ Operable Breast CA SPORE
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated